Here are the top biotech companies you will find in Oxford, a city with an old scientific tradition and an enormous output of biotech applications.
Oxford is well known for its university, one of the oldest in Europe and considered to be one of the best in the world. Recently, the University of Oxford has been the center of attention thanks to an experimental Covid-19 vaccine that the university is developing in partnership with big pharmaceutical companies. If successful, the vaccine, already in phase III testing, could be one of the first to get approval for this new disease.
The University of Oxford has hosted thousands of bright minds over the years. Thanks to its emphasis on technology transfer, the university has also helped a large number of them turn their ideas into successful spinout companies. The environment created around the university has also attracted many talents and businesses to the city, making it the ideal melting pot for new and promising ideas.
Biotech is one of the fortes of the innovation seen in the city of Oxford. So we consulted with local experts to put together a list of the most remarkable companies in the city, be it for their size, innovation, or influence in the sector.
Founded in 2008, Immunocore is one of just a few private biotech companies in Europe that are estimated to be worth over 1B. The company is tackling multiple forms of cancer as well as infectious and autoimmune diseases using T-cell receptor (TCR) technology. TCRs are proteins on the surface of immune T cells that are responsible for identifying a threat that must be destroyed, such as cancerous or infected cells. Immunocore aims to patients with engineered TCRs to circumvent the mechanisms by which these threats evade the immune system, restoring its ability to fight disease.
The company is collaborating on several projects with Genentech, AstraZeneca, Eli Lilly, and GSK. Its most advanced program is a treatment for uveal melanoma that is currently in phase III trials. Other programs target solid tumors, hepatitis, HIV, and type 1 diabetes.
Adaptimmune Therapeutics was founded at the same time as Immunocore with the goal of exploiting TCR technology in the form of T-cell therapy. The company engineers the TCRs naturally present on the patients own immune T cells to improve their ability to identify cancerous cells.
Adaptimmune is now getting ready to start late-stage clinical trials in multiple cancer types. Thanks to a deal with Astellas Pharma, the company is also gearing up to start clinical testing of a version of its T-cell therapy that doesnt require engineering each dose individually for each patient, using donor cells instead. Adaptimmune also has several partnerships with companies including GSK, Noile-Immune Biotech, and Alpine Immune Sciences.
Oxford Biodynamics was spun out of Oxford University in 2007 with the goal of developing liquid biopsy tests that can perform a diagnosis from just a drop of blood. The company specializes in epigenetics, that is changes to the structure of our DNA that determines which genes are switched on or off.
Oxford Biodynamics works in a wide range of indications, including cancer, diabetes, Alzheimers, multiple sclerosis, and rheumatoid arthritis among many others. The tests are not only designed to diagnose a disease; they can also be made to determine which patients are going to benefit the most from a specific drug, and how likely the disease is to progress faster or relapse.
With these tests, the company is supporting the development of personalized medicine approaches and helping drug developers increase their chances of succeeding in clinical trials. Partners include big pharma such as Pfizer and EMD, as well as universities and research institutes.
Chronos Therapeutics started out in 2009 as a spinout of the University of Oxford with the goal of developing drugs for age-related conditions. The companys lead program targets amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, for which there are no treatments able to stop its progression.
Over time, the company has expanded its portfolio into other indications, particularly those that affect the brain, by acquiring assets from third parties. They include programs targeting fatigue caused by multiple sclerosis, addictive behaviors such as binge eating and alcohol use disorder, and post-traumatic stress disorder.
Evox Therapeutics is developing a drug delivery technology based on exosomes nanoparticles that our bodies naturally use to transport molecules. The company engineers exosomes to carry different types of drugs, such as proteins, RNA, or small drugs. The key advantage is that these natural carriers are able to reach targets that conventional drug delivery systems cant, such as the brain.
Founded in 2016, the company has signed big deals with Takeda and Eli Lilly. Its programs are all in preclinical testing and mostly target rare diseases. One of them targets the rare liver disorder argininosuccinic aciduria and is scheduled to enter clinical trials in 2021.
Exscientia is a pioneer in the application of artificial intelligence to drug discovery. The company uses AI to identify potential drug candidates and optimize their structure to maximize their chances of success in clinical trials. The goal is to speed up and reduce the costs of the drug discovery process.
Earlier this year, the companys drug candidate for obsessive-compulsive disorder became one of the first AI-designed drugs to enter clinical trials. While a drug typically takes five years from identification until clinical trials, this one did so in just a year.
Exscientia is partnered with Bayer, BMS, Sanofi, and GSk among others. In the wake of the Covid-19 pandemic, the company set out to go through a database of 15,000 approved and investigational drugs that had already passed safety testing to find candidates that can then be fast-tracked to clinical testing in Covid-19 patients.
Oxford Biomedica was set up in 1995 as a developer and provider of lentiviral vectors for gene and cell therapy. These vectors allow the permanent introduction of a desired DNA sequence into a target cell, be it in the test tube or directly in the patients body.
The technology of Oxford Biomedica is regularly used by companies such as Novartis, Sanofi, Boehringer Ingelheim, Imperial Innovations, and Orchard Therapeutics. Notably, the vectors developed by the company are used in Novartis Kymriah, the first CAR T-cell therapy approved in Europe and the US as a cancer treatment.
Oxford Biomedica also has a preclinical pipeline of proprietary programs in a wide range of applications, including cancer, eye disease, ALS, and liver disease. Last year, the company struck a deal with Microsoft to reduce the complexity and costs of gene and cell therapy manufacturing using artificial intelligence.
Founded in 2016, Arctoris aims to bring the benefits of automation to cancer research. Through the companys services, a researcher could just order an experiment online and spend their valuable time designing experiments and analyzing results rather than performing the repetitive tasks needed to complete them.
Arctoris aims to contribute to reducing the costs of drug discovery, which are increasing every year as treatments become personalized and results more difficult to replicate. In the context of the Covid-19 pandemic, Arctoris has established assays that allow scientists the possibility of running Covid-19 experiments remotely.
Founded in 2015, Orbit Discovery is a drug discovery company focusing on the identification of peptide drugs. The company has developed a technology that significantly improves on conventional methods of drug screening such as phage display or mRNA display.
The technology consists of fusing peptides to the DNA sequence encoding them and presenting them to live cells. This method allows the screening of peptide targets that were previously missed by other technologies, and to study their effect on live cells to better predict their function.
The company has already identified several candidates in the areas of cardiology, immunology, and cancer, and is working with partners such as Zealand Pharma in their preclinical development.
OxStem is a drug discovery company with an unusual approach to stem cell treatments. Instead of using stem cells as a therapy, the firm focuses on developing small molecule drugs that can reprogram the patients own stem cells to treat a wide range of diseases related to aging, including cancer and diabetes as well as neurological, cardiovascular, and ocular conditions.
Founded in 2013, the strategy of OxStem is to spin out companies that specialize in each disease area to focus on the development of the drugs found by the parent company, with five subsidiaries set up so far.
- Stem Cell Research on the Ballot: A Closer Look at Prop 14 - Fullerton Observer - October 18th, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Eurowire - October 18th, 2020
- California Proposition 14: Funding medical research that uses stem cells - KTLA - October 18th, 2020
- World Wide Stem Cell Treatment Centers Provides Exceptional Regenerative Treatment Options To Those in Need - GlobeNewswire - October 18th, 2020
- Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) | DNA RNA and... - October 18th, 2020
- New Therapies in Development for Myelofibrosis - Targeted Oncology - October 18th, 2020
- Heller Heathcare teams up with world-renowed physician - Brunswick News - October 14th, 2020
- Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue... - October 14th, 2020
- The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% -... - October 14th, 2020
- Pair of Lancet studies give final word on a promising Shionogi antibiotic that turned out to be 'as good' as the other 'suboptimal' options -... - October 14th, 2020
- This Dublin-based startup raises 30M to develop promising therapies for leukemia - Silicon Canals - October 14th, 2020
- Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis - Targeted Oncology - October 12th, 2020
- Trumps Covid Treatments Were Tested in Cells Derived From Fetal Tissue - The New York Times - October 12th, 2020
- Singapore startup Shiok Meats re-creates shrimp in the lab - Los Angeles Times - October 10th, 2020
- Kathriona Devereux: Biscuits, Netflix, no chores... the benefits of breastfeeding! - Echo Live - October 10th, 2020
- Current and Emerging Treatments in Follicular Lymphoma - OncLive - October 10th, 2020
- Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use - Salon - October 8th, 2020
- Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets - BioWorld Online - October 8th, 2020
- The Recovery Room: News beyond the pandemic October 2 - Medical News Today - October 8th, 2020
- EUROPE The General Court Limits the Scope of Satisfactory Methods That Must Be Compared for Orphan Drug Designation - JD Supra - October 8th, 2020
- What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED - October 2nd, 2020
- Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations - BioSpace - October 2nd, 2020
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - The Daily Chronicle - October 2nd, 2020
- FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration - PR Newswire UK - October 2nd, 2020
- Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering... - October 2nd, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Global Industry COVID 19 Analysis, Growth Trends and Forecast 2019-2026 - The Daily... - October 2nd, 2020
- The Europe exosome diagnostic and therapeutic market is projected to reach US$ 12,524.24 thousand in 2019 to US$ 104,694.72 thousand by 2027 - Yahoo... - October 2nd, 2020
- Exosome Therapeutic Market Latest Industry Size, Growth, Share, Emerging Demands, and Competitive Landscape || Major Gaints Jazz Pharmaceuticals,... - September 29th, 2020
- Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies - GlobeNewswire - September 29th, 2020
- Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I - BioSpace - September 29th, 2020
- JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy - GlobeNewswire - September 29th, 2020
- Top Benefits of Stem Cell Therapy Know Your Health - September 26th, 2020
- 10 Benefits of a Stem Cell Treatment | Advanced Sports ... - September 26th, 2020
- New Data Highlights BeyondSpring's Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce... - September 26th, 2020
- Virtual Castellvi Spine Week 2: Living Cells and Therapies - https://ryortho.com/ - September 26th, 2020
- Get Up to Speed On the State of Eco-Fashion - NEO.LIFE - September 26th, 2020
- Global Cell Culture Market and Technology Forecast 2020-2028 - Global Market Forecast to Reach USD 48 Billion for 2028 - ResearchAndMarkets.com -... - September 24th, 2020
- Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients - Curetoday.com - September 24th, 2020
- Global Cord Blood Banking Market is Anticipate to Reach at a CAGR of 5.5% during the forecast period - PharmiWeb.com - September 24th, 2020
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to... - September 24th, 2020
- Lab-grown meat: The promising alternative that may be years away from appearing on dinner plates - PitchBook News & Analysis - September 24th, 2020
- Bioprinted therapeutic offers novel solution for treating Type 1 Diabetes - Canada NewsWire - September 24th, 2020
- Yulong to List its Securitized Token on CryptoSX - BioSpace - September 24th, 2020
- 10 Top Stem Cell Companies on the NASDAQ | INN - Investing News Network - September 22nd, 2020
- The Anti-aging Benefits of Using Growth Factors Plus Retinol - Coveteur - September 22nd, 2020
- Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS (ravulizumab) with Significantly Reduced Infusion Time - Business... - September 22nd, 2020
- Why Celebs and Athletes Are Embracing Blood Flow Restriction Training - menshealth.com - September 22nd, 2020
- Yulong to Issue the Worlds' First Biotech Securitized Token Offering - StreetInsider.com - September 22nd, 2020
- Market trends and outlook coupled with factors driving and restraining the growth of the CRISPR Genome Editing market - The Daily Chronicle - September 22nd, 2020
- COVID is shifting the conversation about the medical application of CBD - Open Access Government - September 22nd, 2020
- Merck's KEYTRUDA (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk... - September 22nd, 2020
- Regenerative Therapy by Dr. Roshni Patel on Better CT - Farmington, CT - Patch.com - September 20th, 2020
- Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously... - September 20th, 2020
- CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR... - September 18th, 2020
- Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation - nejm.org - September 18th, 2020
- Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 - Business Wire - September 18th, 2020
- Faulty exon splicing is cause of rare subtype of Parkinson's disease, pointing to new drug targets - BioWorld Online - September 15th, 2020
- Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain... - September 13th, 2020
- Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men - StreetInsider.com - September 13th, 2020
- BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both US FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia... - September 8th, 2020
- Hematopoietic Stem Cells (HSCs) Market 2020: Potential Growth, Challenges, and Know the Impact of COVID-19 on Industry | Key Players: Kite Pharma... - September 8th, 2020
- Stem Cell Therapy Market Scope and Opportunities Analysis 2017 2025 - StartupNG - August 31st, 2020
- Im Optimistic That We Will Have a COVID-19 Vaccine Soon - The Atlantic - August 31st, 2020
- Health insurance with maternity cover: All you need to know about features and inclusions - CNBCTV18 - August 31st, 2020
- Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections - DocWire News - August 31st, 2020
- MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th... - August 31st, 2020
- Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United... - August 20th, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 20th, 2020
- Animal Stem Cell Therapy Market: Rising Demand and Growth Opportunity - Owned - August 20th, 2020
- Health Spotlight: Have You Heard Of Dr. Jeffrey Tucker? - LATF USA - August 20th, 2020
- Viruses have big impacts on ecology and evolution as well as human health - The Economist - August 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With... - August 20th, 2020
- Umbilical cord blood banking: Is it worth it? - mtltimes.ca - August 19th, 2020
- G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer - GlobeNewswire - August 19th, 2020
- A question of scale the growing pains of cell-based meat - just-food.com - August 19th, 2020
- What do we need to know about our bone health during this pandemic - Times of India - August 19th, 2020
- Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research - Business Wire India - August 19th, 2020
- Cellect Biotechnology Ltd ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for Stem Cells Activation from the European Patent Office - BP... - August 13th, 2020
- A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeuticrelated cytokine release syndrome - Wiley - August 13th, 2020
- Autologous Stem Cell Based Therapies Industry Market 2020 Explain What is the current size of the market? And key players analysis: Athersys,... - August 13th, 2020